Cargando…

Influence of Five Potential Anticancer Drugs on Wnt Pathway and Cell Survival in Human Biliary Tract Cancer Cells

Background: The role of Wnt signalling in carcinogenesis suggests compounds targeting this pathway as potential anti-cancer drugs. Several studies report activation of Wnt signalling in biliary tract cancer (BTC) thus rendering Wnt inhibitory drugs as potential candidates for targeted therapy of thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	WACHTER, Julia, NEUREITER, Daniel, ALINGER, Beate, PICHLER, Martin, FUEREDER, Julia, OBERDANNER, Christian, Di FAZIO, Pietro, OCKER, Matthias, BERR, Frieder, KIESSLICH, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2011
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226029/ https://www.ncbi.nlm.nih.gov/pubmed/22211101

Ejemplares similares

The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells
por: Mayr, Christian, et al.
Publicado: (2015)

Biliary tract cancer stem cells - translational options and challenges
por: Mayr, Christian, et al.
Publicado: (2017)

The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells
por: Mayr, Christian, et al.
Publicado: (2015)

MicroRNAs Associated with the Efficacy of Photodynamic Therapy in Biliary Tract Cancer Cell Lines
por: Wagner, Andrej, et al.
Publicado: (2014)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients
por: Urbas, Romana, et al.
Publicado: (2016)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
por: Zopf, Steffen, et al.
Publicado: (2012)

Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma
por: Bekric, Dino, et al.
Publicado: (2023)

Ouabain at nanomolar concentrations is cytotoxic for biliary tract cancer cells
por: Mayr, Christian, et al.
Publicado: (2023)

Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers
por: Mayr, Christian, et al.
Publicado: (2016)

NRF2: The key to tumor- and patient-dependent chemosensitivity in biliary tract cancer?
por: Kiesslich, Tobias, et al.
Publicado: (2019)

Long Non-Coding RNAs in Biliary Tract Cancer—An Up-to-Date Review
por: Bekric, Dino, et al.
Publicado: (2020)

The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications
por: Klieser, Eckhard, et al.
Publicado: (2019)

Systematic Review on Optical Diagnosis of Early Gastrointestinal Neoplasia
por: Wagner, Andrej, et al.
Publicado: (2021)

Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
por: Neureiter, Daniel, et al.
Publicado: (2019)

The Cancer Stem Cell Inhibitor Napabucasin (BBI608) Shows General Cytotoxicity in Biliary Tract Cancer Cells and Reduces Cancer Stem Cell Characteristics
por: Beyreis, Marlena, et al.
Publicado: (2019)

Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future
por: Ocker, Matthias, et al.
Publicado: (2021)

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
por: Di Fazio, Pietro, et al.
Publicado: (2010)

Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
por: Bekric, Dino, et al.
Publicado: (2023)

Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation
por: Bekric, Dino, et al.
Publicado: (2022)

Endoscopic on-site characterization of a large excavated lesion in longstanding ulcerative colitis using a novel bioinformatic tool
por: Wagner, Andrej, et al.
Publicado: (2023)

Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells
por: Wanek, Julia, et al.
Publicado: (2018)

New method for real-time visualization and quantitative characterization of early colorectal cancer in endoscopy: a pilot study
por: Wagner, Andrej, et al.
Publicado: (2022)

Continuous, label-free, 96-well-based determination of cell migration using confluence measurement
por: Mayr, Christian, et al.
Publicado: (2018)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
por: Mayr, Christian, et al.
Publicado: (2021)

Can We Efficiently Target HDAC in Cancer?
por: Kiesslich, Tobias, et al.
Publicado: (2022)

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer
por: Di Fazio, Pietro, et al.
Publicado: (2016)

Differential Bone Marrow Homing Capacity of VLA-4 and CD38 High Expressing Chronic Lymphocytic Leukemia Cells
por: Brachtl, Gabriele, et al.
Publicado: (2011)

MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms
por: Posch, Florian, et al.
Publicado: (2021)

Neoadjuvant Down-Sizing of Hilar Cholangiocarcinoma with Photodynamic Therapy—Long-Term Outcome of a Phase II Pilot Study †
por: Wagner, Andrej, et al.
Publicado: (2015)

Generation of An Endogenous FGFR2–BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells
por: Reicher, Andreas, et al.
Publicado: (2020)

Miniaturization of the Clonogenic Assay Using Confluence Measurement
por: Mayr, Christian, et al.
Publicado: (2018)

HDAC-Linked “Proliferative” miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors
por: Klieser, Eckhard, et al.
Publicado: (2018)

GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?
por: Illig, Romana, et al.
Publicado: (2013)

Leberversagen
por: Berr, Frieder, et al.
Publicado: (2007)

bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells
por: Okamoto, Kinya, et al.
Publicado: (2007)

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
por: Ellinghaus, Peter, et al.
Publicado: (2022)

Leberversagen
por: Berr, Frieder, et al.
Publicado: (2005)

Overview of Major Classes of Plant-Derived Anticancer Drugs
por: Amin, Amr, et al.
Publicado: (2009)

The Wnt Antagonist sFRP1 as a Favorable Prognosticator in Human Biliary Tract Carcinoma
por: Kang, Pengcheng, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f0cm6h106ebc7n0a2i3td1i54b